Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 in HER2-low metastatic breast cancer
NCT06957886Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BL-M07D1 in breast cancer (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Progression-Free Survival at 24 months. Started May 2025; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06957886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957886.